Growing evidence has indicated that genes of the SGOC metabolism can serve as prognostic markers and potential therapeutic targets for tumor treatment.32 To better understand the clinical application potential of the SGOC network in HNSCC, we developed a novel classifier of a 4-gene SGOC prognostic signature (PRT1, TBPL1, PLOD2, and SLC44A4). The gene discussed is PLOD2; the disease is head and neck squamous cell carcinoma.